Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation reported its Q4 and full year 2025 results, highlighting successful dosing in the SAD portion of its ABS-201 Phase 1/2a trial for androgenetic alopecia with favorable safety data. The company unveiled ex vivo data showing ABS-201 stimulates hair growth and regenerates follicle stem cell niches. Absci appointed Dr. Ransi Somaratne …